Bank of Nova Scotia Reduces Position in Bristol-Myers Squibb (NYSE:BMY)
Bank of Nova Scotia Reduces Position in Bristol-Myers Squibb (NYSE:BMY)
Bank of Nova Scotia lessened its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 81.2% during the 1st quarter, Holdings Channel reports. The firm owned 316,586 shares of the biopharmaceutical company's stock after selling 1,363,989 shares during the quarter. Bank of Nova Scotia's holdings in Bristol-Myers Squibb were worth $23,120,000 as of its most recent filing with the Securities and Exchange Commission.
据控股频道报道，丰业银行在第一季度减持了百时美施贵宝(纽约证券交易所代码：BMY-GET评级)81.2%的股份。该公司在本季度出售了1,363,989股后，持有这家生物制药公司316,586股股票。根据百时美施贵宝最近提交给美国证券交易委员会的文件，丰业银行持有的百时美施贵宝价值2312万美元。
Several other large investors also recently bought and sold shares of the stock. Cahaba Wealth Management Inc. boosted its holdings in shares of Bristol-Myers Squibb by 2.5% in the 1st quarter. Cahaba Wealth Management Inc. now owns 5,391 shares of the biopharmaceutical company's stock valued at $405,000 after acquiring an additional 132 shares during the last quarter. MV Capital Management Inc. boosted its holdings in shares of Bristol-Myers Squibb by 10.7% in the 1st quarter. MV Capital Management Inc. now owns 1,391 shares of the biopharmaceutical company's stock valued at $102,000 after acquiring an additional 135 shares during the last quarter. Sanders Morris Harris LLC boosted its holdings in shares of Bristol-Myers Squibb by 0.3% in the 1st quarter. Sanders Morris Harris LLC now owns 40,501 shares of the biopharmaceutical company's stock valued at $2,958,000 after acquiring an additional 137 shares during the last quarter. Bernardo Wealth Planning LLC boosted its holdings in shares of Bristol-Myers Squibb by 4.3% in the 1st quarter. Bernardo Wealth Planning LLC now owns 3,389 shares of the biopharmaceutical company's stock valued at $247,000 after acquiring an additional 139 shares during the last quarter. Finally, Stiles Financial Services Inc boosted its holdings in shares of Bristol-Myers Squibb by 2.3% in the 1st quarter. Stiles Financial Services Inc now owns 6,368 shares of the biopharmaceutical company's stock valued at $465,000 after acquiring an additional 141 shares during the last quarter. Hedge funds and other institutional investors own 73.07% of the company's stock.
其他几家大型投资者最近也买卖了该股的股票。Cahaba Wealth Management Inc.在第一季度增持了2.5%的百时美施贵宝股票。卡哈巴财富管理公司(Cahaba Wealth Management Inc.)目前持有这家生物制药公司5,391股股票，价值40.5万美元，该公司在上个季度增持了132股股票。MV Capital Management Inc.在第一季度增持了10.7%的百时美施贵宝股票。MV Capital Management Inc.现在持有这家生物制药公司1,391股股票，价值10.2万美元，该公司在上个季度增持了135股。桑德斯·莫里斯·哈里斯有限责任公司在第一季度将百时美施贵宝的股票持有量增加了0.3%。桑德斯·莫里斯·哈里斯有限责任公司(Sanders Morris Harris LLC)现在拥有这家生物制药公司40,501股股票，价值2,958,000美元，此前在上个季度又购买了137股。Bernardo Wealth Program LLC在第一季度增持了4.3%的百时美施贵宝股票。贝尔纳多财富规划有限责任公司现在拥有3389股这家生物制药公司的股票，价值24.7万美元，在上个季度额外购买了139股。最后，斯泰尔斯金融服务公司在第一季度增持了2.3%的百时美施贵宝股票。斯泰尔斯金融服务公司现在拥有6,368股这家生物制药公司的股票，价值465,000美元，在上个季度额外购买了141股。对冲基金和其他机构投资者持有该公司73.07%的股票。
Analyst Upgrades and Downgrades
分析师升级和下调评级
BMY has been the subject of several analyst reports. Barclays boosted their target price on shares of Bristol-Myers Squibb from $66.00 to $68.00 in a research note on Monday, May 2nd. Wells Fargo & Company upped their price objective on shares of Bristol-Myers Squibb from $65.00 to $70.00 and gave the stock an "equal weight" rating in a research report on Tuesday, May 17th. Truist Financial upped their target price on shares of Bristol-Myers Squibb from $76.00 to $81.00 in a report on Monday, May 2nd. Bank of America upped their target price on shares of Bristol-Myers Squibb from $78.00 to $80.00 and gave the stock a "buy" rating in a report on Monday, June 6th. Finally, BMO Capital Markets upped their target price on shares of Bristol-Myers Squibb from $87.00 to $92.00 in a report on Monday, May 2nd. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $75.57.
BMY一直是几份分析师报告的主题。巴克莱在5月2日星期一的一份研究报告中将百时美施贵宝的股票目标价从66.00美元上调至68.00美元。在5月17日周二的一份研究报告中，富国银行将百时美施贵宝的股票目标价从65.00美元上调至70.00美元，并给予该股“同等权重”的评级。在5月2日星期一的一份报告中，Truist Financial将百时美施贵宝的股票目标价从76.00美元上调至81.00美元。在6月6日周一的一份报告中，美国银行将百时美施贵宝的股票目标价从78.00美元上调至80.00美元，并给予该股“买入”评级。最后，蒙特利尔银行资本市场在5月2日星期一的一份报告中将百时美施贵宝的股票目标价从87.00美元上调至92.00美元。一位研究分析师对该股的评级为卖出，4位分析师发布了持有评级，7位分析师发布了买入评级，一位分析师给予了该公司强烈的买入评级。根据MarketBeat.com的数据，该公司的平均评级为“中等买入”，平均目标价为75.57美元.
Insiders Place Their Bets
内部人士下注
Bristol-Myers Squibb Trading Down 0.5 %
百时美施贵宝股价下跌0.5%
Shares of BMY stock opened at $74.46 on Friday. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.44 and a quick ratio of 1.34. The firm has a market cap of $158.99 billion, a PE ratio of 24.74, a price-to-earnings-growth ratio of 1.59 and a beta of 0.40. The company has a 50-day moving average of $74.94 and a two-hundred day moving average of $73.00. Bristol-Myers Squibb has a 1-year low of $53.22 and a 1-year high of $80.59.
上周五，BMY股票开盘报74.46美元。该公司的债务权益比为1.14，流动比率为1.44，速动比率为1.34。该公司市值为1,589.9亿美元，市盈率为24.74倍，市盈率为1.59倍，贝塔系数为0.40。该公司的50日移动均线切入位在74.94美元，200日移动均线切入位在73.00美元。百时美施贵宝的一年低点为53.22美元，一年高位为80.59美元。
Bristol-Myers Squibb (NYSE:BMY – Get Rating) last announced its earnings results on Wednesday, July 27th. The biopharmaceutical company reported $1.93 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.14. The company had revenue of $11.89 billion during the quarter, compared to analyst estimates of $11.50 billion. Bristol-Myers Squibb had a net margin of 14.04% and a return on equity of 49.31%. Bristol-Myers Squibb's revenue was up 1.6% compared to the same quarter last year. During the same quarter last year, the firm posted $1.93 earnings per share. On average, analysts predict that Bristol-Myers Squibb will post 7.53 EPS for the current year.
百时美施贵宝(纽约证券交易所代码：BMY-GET评级)最近一次公布收益结果是在7月27日星期三。这家生物制药公司公布本季度每股收益为1.93美元，比普遍预期的1.79美元高出0.14美元。该公司本季度营收为118.9亿美元，而分析师预期为115亿美元。百时美施贵宝的净利润率为14.04%，股本回报率为49.31%。与去年同期相比，百时美施贵宝的收入增长了1.6%。去年同一季度，该公司公布的每股收益为1.93美元。分析师平均预测，百时美施贵宝本年度每股收益将达到7.53欧元。
Bristol-Myers Squibb Announces Dividend
百时美施贵宝宣布分红
The business also recently announced a quarterly dividend, which was paid on Monday, August 1st. Shareholders of record on Friday, July 1st were paid a dividend of $0.54 per share. This represents a $2.16 annualized dividend and a yield of 2.90%. The ex-dividend date of this dividend was Thursday, June 30th. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently 71.76%.
该公司最近还宣布了季度股息，股息于8月1日(星期一)支付。7月1日(星期五)登记在册的股东获得了每股0.54美元的股息。这意味着年化股息为2.16美元，收益率为2.90%。本次股息除息日期为6月30日星期四。百时美施贵宝的股息支付率(DPR)目前为71.76%。
Bristol-Myers Squibb Profile
百时美施贵宝简介
(Get Rating)
(获取评级)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
百时美施贵宝公司在全球发现、开发、许可、制造和营销生物制药产品。它提供血液学、肿瘤学、心血管学、免疫学、纤维化、神经科学和新冠肺炎疾病的产品。该公司的产品包括治疗多发性骨髓瘤的口服免疫调节药物Revlimid；用于降低NVAF中风/系统性栓塞风险和治疗DVT/PE的口服抑制剂Eiquis；用于抗癌适应症的Opdivo；用于多发性骨髓瘤患者的Pomalyst/Imnovid；以及用于成人活动期RA和牛皮癣关节炎的Orencia。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Bristol-Myers Squibb (BMY)
- Can You Guess Which EV Stock Is Beating Tesla ?
- Look at Honeywell for a Steady and Diversified Stock
- Why Invest in High-Yield Dividend Stocks?
- Find and Profitably Trade Stocks at 52-Week Lows
- Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
- 免费获取StockNews.com关于百时美施贵宝(BMY)的研究报告
- 你能猜到哪个电动车股票打败了特斯拉吗？
- 霍尼韦尔看好稳定和多元化的股票
- 为什么要投资高收益股利股票？
- 找到并获利于52周低点的股票交易
- 迪士尼(NYSE：DIS)的股票刚刚给了投资者一个巨大的信号
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Get Rating).
想看看其他对冲基金持有哪些BMY吗？访问HoldingsChannel.com获取百时美施贵宝(纽约证券交易所代码：BMY-GET Rating)的最新13F备案文件和内幕交易信息。
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
接受百时美施贵宝日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对百时美施贵宝及相关公司评级的每日摘要。
译文内容由第三方软件翻译。